Treating the Experience.
Our Pipeline
Moving beyond traditional therapies, we aim to improve adherence journeys for patients’ needs.
Indication
Early Development
Animal Studies
Human Studies
Phase 1
Phase 2
Phase 3
Anticipated NDA/BLA Submission Status
SCN-102 | CVS/Hypertension
Oral suspension for geriatric and pediatric use
SCN-104 | CNS/Pain
Drug device combination for convenient self-injection
SCN-106 | CVS
Biosimilar product for hospital use
SCN-107 | CNS/Pain
Long-acting injection for post-operative care
Completed
To be performed
Indication
SCN-102 | CVS/Hypertension
Oral suspension for geriatric and pediatric use
Early Development
Animal Studies
Anticipated NDA/BLA Submission Status
Human Studies
Phase 1
Phase 2
Phase 3
Indication
SCN-104 | CNS/Pain
Drug device combination for convenient self-injection
Early Development
Animal Studies
Human Studies
Phase 1
Phase 2
Phase 3
Indication
SCN-106 | CVS
Biosimilar product for hospital use
Early Development
Human Studies
Phase 1
Phase 2
Phase 3
Indication
SCN-107 | CNS/Pain
Long-acting injection for post-operative care
Early Development
Animal Studies
Human Studies
Phase 1
Phase 2
Phase 3
Completed
To be performed
Partnering for Impactful Solutions
At Scienture, we value bold ideas grounded in evidence-based solutions, balancing innovation with measurable impact on patient care.
Contact us to explore partnership opportunities in product licensing, co-marketing, or asset acquisitions to shape the future of healthcare together.